RXi Pharmaceuticals (RXII) Scheduled to Post Quarterly Earnings on Tuesday

RXi Pharmaceuticals (NASDAQ:RXII) is scheduled to announce its earnings results after the market closes on Tuesday, August 14th. Analysts expect the company to announce earnings of ($0.59) per share for the quarter.

RXi Pharmaceuticals (NASDAQ:RXII) last posted its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.90) EPS for the quarter. The company had revenue of $0.02 million for the quarter. On average, analysts expect RXi Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

RXi Pharmaceuticals opened at $1.64 on Friday, Marketbeat.com reports. The stock has a market capitalization of $6.47 million, a P/E ratio of -0.39 and a beta of 1.31. RXi Pharmaceuticals has a 12 month low of $1.29 and a 12 month high of $7.70.

Several research analysts recently commented on RXII shares. HC Wainwright set a $3.00 price target on shares of RXi Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 2nd. ValuEngine raised shares of RXi Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

See Also: Growth Stocks

Earnings History for RXi Pharmaceuticals (NASDAQ:RXII)

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply